RecruitingPhase 1 / Phase 2NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Sponsor: Daiichi Sankyo
Los Angeles, CA · Whittier, CA · +15 more sites